Published in J Virol on February 01, 2005
A putative thiamine transport protein is a receptor for feline leukemia virus subgroup A. J Virol (2006) 1.17
Feline leukemia virus and other pathogens as important threats to the survival of the critically endangered Iberian lynx (Lynx pardinus). PLoS One (2009) 1.12
Unique long terminal repeat and surface glycoprotein gene sequences of feline leukemia virus as determinants of disease outcome. J Virol (2005) 0.98
Genetic characterization of feline leukemia virus from Florida panthers. Emerg Infect Dis (2008) 0.92
Phylogenetic and structural diversity in the feline leukemia virus env gene. PLoS One (2013) 0.90
Viral determinants of FeLV infection and pathogenesis: lessons learned from analysis of a natural cohort. Viruses (2011) 0.87
Emerging viruses in the Felidae: shifting paradigms. Viruses (2012) 0.85
Advances in understanding molecular determinants in FeLV pathology. Vet Immunol Immunopathol (2008) 0.83
Distinctive receptor binding properties of the surface glycoprotein of a natural feline leukemia virus isolate with unusual disease spectrum. Retrovirology (2011) 0.82
Dominance of highly divergent feline leukemia virus A progeny variants in a cat with recurrent viremia and fatal lymphoma. Retrovirology (2010) 0.80
Identification of novel subgroup A variants with enhanced receptor binding and replicative capacity in primary isolates of anaemogenic strains of feline leukaemia virus. Retrovirology (2012) 0.78
Diminished potential for B-lymphoid differentiation after murine leukemia virus infection in vivo and in EML hematopoietic progenitor cells. J Virol (2007) 0.77
The frequency of occurrence and nature of recombinant feline leukemia viruses in the induction of multicentric lymphoma by infection of the domestic cat with FeLV-945. Virology (2010) 0.77
Human T lymphotropic virus type 1 SU residue 195 plays a role in determining the preferential CD4+ T cell immortalization/transformation tropism. J Virol (2013) 0.76
The surface glycoprotein of feline leukemia virus isolate FeLV-945 is a determinant of altered pathogenesis in the presence or absence of the unique viral long terminal repeat. J Virol (2013) 0.75
Feline models of viral pathogenesis: opportunity knocks. Vet J (2010) 0.75
The surface glycoprotein of a natural feline leukemia virus subgroup A variant, FeLV-945, as a determinant of disease outcome. Vet Immunol Immunopathol (2011) 0.75
Presence of a Shared 5'-Leader Sequence in Ancestral Human and Mammalian Retroviruses and its Transduction into Feline Leukemia Virus. J Virol (2017) 0.75
Isolation of cDNA clones encoding T cell-specific membrane-associated proteins. Nature (1984) 8.89
Receptor choice determinants in the envelope glycoproteins of amphotropic, xenotropic, and polytropic murine leukemia viruses. J Virol (1992) 4.58
Cell-surface receptors for gibbon ape leukemia virus and amphotropic murine retrovirus are inducible sodium-dependent phosphate symporters. Proc Natl Acad Sci U S A (1994) 4.07
Molecular cloning of a feline leukemia virus that induces fatal immunodeficiency disease in cats. Science (1988) 2.86
Feline leukemia virus subgroup B uses the same cell surface receptor as gibbon ape leukemia virus. J Virol (1992) 2.80
Strong sequence conservation among horizontally transmissible, minimally pathogenic feline leukemia viruses. J Virol (1988) 2.62
Nucleotide sequences of a feline leukemia virus subgroup A envelope gene and long terminal repeat and evidence for the recombinational origin of subgroup B viruses. J Virol (1986) 2.34
Functional dissection of the Moloney murine leukemia virus envelope protein gp70. J Virol (1997) 2.24
The cellular receptor for gibbon ape leukemia virus is a novel high affinity sodium-dependent phosphate transporter. J Biol Chem (1994) 2.22
Selection forces and constraints on retroviral sequence variation. Science (2001) 2.17
Molecular analysis and pathogenesis of the feline aplastic anemia retrovirus, feline leukemia virus C-Sarma. J Virol (1986) 1.84
Viral genetic determinants of T-cell killing and immunodeficiency disease induction by the feline leukemia virus FeLV-FAIDS. J Virol (1991) 1.83
Activation of a cell entry pathway common to type C mammalian retroviruses by soluble envelope fragments. J Virol (2000) 1.72
Cloning of the cellular receptor for feline leukemia virus subgroup C (FeLV-C), a retrovirus that induces red cell aplasia. Blood (2000) 1.64
Identification of a cellular cofactor required for infection by feline leukemia virus. Science (2000) 1.49
A putative cell surface receptor for anemia-inducing feline leukemia virus subgroup C is a member of a transporter superfamily. J Virol (1999) 1.48
Variable regions A and B in the envelope glycoproteins of feline leukemia virus subgroup B and amphotropic murine leukemia virus interact with discrete receptor domains. J Virol (1997) 1.44
Three distinct envelope domains, variably present in subgroup B feline leukemia virus recombinants, mediate Pit1 and Pit2 receptor recognition. J Virol (1997) 1.41
Feline leukemia virus infection and diseases. J Am Vet Med Assoc (1991) 1.37
Feline leukaemia virus: generation of pathogenic and oncogenic variants. Curr Top Microbiol Immunol (1991) 1.32
A point mutation in the binding subunit of a retroviral envelope protein arrests virus entry at hemifusion. J Virol (2004) 1.30
Nucleotide sequences of the envelope genes of two isolates of feline leukemia virus subgroup B. J Virol (1984) 1.26
In vivo evolution of a novel, syncytium-inducing and cytopathic feline leukemia virus variant. J Virol (1998) 1.23
Endogenous env elements: partners in generation of pathogenic feline leukemia viruses. Virus Genes (1995) 1.20
Feline leukemia virus subgroup C phenotype evolves through distinct alterations near the N terminus of the envelope surface glycoprotein. Proc Natl Acad Sci U S A (1992) 1.18
Identification of envelope determinants of feline leukemia virus subgroup B that permit infection and gene transfer to cells expressing human Pit1 or Pit2. J Virol (2001) 1.18
Fusion-defective gibbon ape leukemia virus vectors can be rescued by homologous but not heterologous soluble envelope proteins. J Virol (2002) 1.16
Evolution of feline leukemia virus variant genomes with insertions, deletions, and defective envelope genes in infected cats with tumors. J Virol (1994) 1.16
flvi-1, a common integration domain of feline leukemia virus in naturally occurring lymphomas of a particular type. J Virol (1990) 1.15
Genetic determinants of feline leukemia virus-induced multicentric lymphomas. Virology (1995) 1.15
Specificity in receptor usage by T-cell-tropic feline leukemia viruses: implications for the in vivo tropism of immunodeficiency-inducing variants. J Virol (2001) 1.15
Function of a unique sequence motif in the long terminal repeat of feline leukemia virus isolated from an unusual set of naturally occurring tumors. J Virol (1995) 1.13
Feline leukemia virus: pathogenesis of neoplastic disease. Cancer Invest (1992) 1.06
Feline leukemia virus envelope sequences that affect T-cell tropism and syncytium formation are not part of known receptor-binding domains. J Virol (2000) 1.03
Feline lymphomas: immunological and cytochemical characterization. Cancer Res (1989) 1.00
Feline leukaemia virus LTR variation and disease association in a geographical and temporal cluster. J Gen Virol (2004) 0.98
Interference with superinfection and with cell killing and determination of host range and growth kinetics mediated by feline leukemia virus surface glycoproteins. J Virol (1993) 0.98
Pathogenicity induced by feline leukemia virus, Rickard strain, subgroup A plasmid DNA (pFRA). J Virol (1998) 0.97
A virus-virus interaction circumvents the virus receptor requirement for infection by pathogenic retroviruses. J Virol (2003) 0.96
The FeLV-945 LTR confers a replicative advantage dependent on the presence of a tandem triplication. Virology (1999) 0.91
Regulation of FeLV-945 by c-Myb binding and CBP recruitment to the LTR. Virol J (2004) 0.90
Feline leukemia virus: pathophysiology, prevention, and treatment. Cancer Invest (1992) 0.83
Genetic and biochemical analyses of receptor and cofactor determinants for T-cell-tropic feline leukemia virus infection. J Virol (2002) 0.83
Feline leukaemia virus LTR variation and disease association in a geographical and temporal cluster. J Gen Virol (2004) 0.98
Unique long terminal repeat and surface glycoprotein gene sequences of feline leukemia virus as determinants of disease outcome. J Virol (2005) 0.98
Disruption of hematopoiesis and thymopoiesis in the early premalignant stages of infection with SL3-3 murine leukemia virus. J Virol (2002) 0.96
Regulation of FeLV-945 by c-Myb binding and CBP recruitment to the LTR. Virol J (2004) 0.90
Viral determinants of FeLV infection and pathogenesis: lessons learned from analysis of a natural cohort. Viruses (2011) 0.87
Growth regulation of simian and human AIDS-related non-Hodgkin's lymphoma cell lines by TGF-beta1 and IL-6. BMC Cancer (2007) 0.83
Matrix attachment regions as targets for retroviral integration. Virol J (2005) 0.82
Distinctive receptor binding properties of the surface glycoprotein of a natural feline leukemia virus isolate with unusual disease spectrum. Retrovirology (2011) 0.82
Apoptotic induction in B-cell acute lymphoblastic leukemia cell lines treated with a protein kinase Cβ inhibitor. Leuk Lymphoma (2011) 0.79
Diminished potential for B-lymphoid differentiation after murine leukemia virus infection in vivo and in EML hematopoietic progenitor cells. J Virol (2007) 0.77
The frequency of occurrence and nature of recombinant feline leukemia viruses in the induction of multicentric lymphoma by infection of the domestic cat with FeLV-945. Virology (2010) 0.77
Protein kinase C-beta inhibition induces apoptosis and inhibits cell cycle progression in acquired immunodeficiency syndrome-related non-hodgkin lymphoma cells. J Investig Med (2012) 0.77
Retrospective analysis of clinical and laboratory factors associated with lymphoma in simian AIDS. Leuk Lymphoma (2004) 0.76
The surface glycoprotein of a natural feline leukemia virus subgroup A variant, FeLV-945, as a determinant of disease outcome. Vet Immunol Immunopathol (2011) 0.75
The surface glycoprotein of feline leukemia virus isolate FeLV-945 is a determinant of altered pathogenesis in the presence or absence of the unique viral long terminal repeat. J Virol (2013) 0.75
A thank you from Tulane University. Science (2007) 0.75
Use of CPR in hemorrhagic shock, a dog model. J Trauma Acute Care Surg (2016) 0.75